MedTrace Logo

Lacticaseibacillus Rhamnosus GG Pili Study

NCT05461443 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2022-07-18

No results posted yet for this study

Summary

The aim of this study was to investigate the host-microbe interaction effects of various Lacticaseibacillus rhamnosus GG strains, with different binding capacities to the mucus in the small intestine, in healthy individuals

Conditions

  • Healthy

Interventions

DIETARY_SUPPLEMENT

Probiotic

Sponsors & Collaborators

  • Valio Ltd

    collaborator INDUSTRY

  • Chr Hansen

    collaborator INDUSTRY

  • Örebro University, Sweden

    lead OTHER

Principal Investigators

  • Robert Brummer, Professor · Örebro University, School of Medical Sciences, Sweden

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-03-31
Primary Completion
2017-06-30
Completion
2017-06-30

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05461443 on ClinicalTrials.gov